RASP Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 12:28):

Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma...

Stats
Today's Volume	120.00
Average Volume	251.00
Market Cap	13.35M
EPS	$-0.000140 ( 2023-06-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.730
ATR14	$0.00100 (5.78%)

Volume Correlation

Long: 0.02 (neutral)

Short: -0.23 (neutral)

Signal:(72.063) Neutral

Rasna Therapeutics, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Rasna Therapeutics, Inc. Correlation - Currency/Commodity

-0.68
( moderate negative )

-0.71
( moderate negative )

0.00
( neutral )

0.26
( neutral )

Rasna Therapeutics, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.00770

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.00770

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.00510

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0114

Financial Reports:

No articles found.

Rasna Therapeutics, Inc.

Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma. It focuses on developing small molecule drug candidates targeting NPM1 and LSD1, which are implicated in the disease progression of leukemia and lymphoma. The company is developing RASP-201 (LSD1), an enzyme that demethylates lysine side chain of histones; and RASP-301, an NPM1 gene that provides instructions for making nucleophosmin protein. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York.